• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    3/15/24 5:33:52 PM ET
    $ACON
    $ALGS
    $ATXI
    $AUTL
    Medical Specialities
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • Cue Health (NASDAQ:HLTH) shares increased by 12.1% to $0.22 during Friday's after-market session. The company's market cap stands at $34.8 million. As per the press release, Q4 earnings came out 2 days ago.
    • Aclarion (NASDAQ:ACON) shares increased by 10.39% to $0.44. The market value of their outstanding shares is at $3.1 million.
    • BioSig Technologies (NASDAQ:BSGM) shares increased by 9.39% to $0.58. The market value of their outstanding shares is at $5.4 million.
    • OptiNose (NASDAQ:OPTN) stock increased by 9.09% to $2.04. The company's market cap stands at $229.8 million.
    • SCWorx (NASDAQ:WORX) stock rose 7.55% to $1.85. The market value of their outstanding shares is at $2.2 million.
    • Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 7.3% to $0.17. The market value of their outstanding shares is at $6.3 million.

    Losers

    • Molecular Templates (NASDAQ:MTEM) shares declined by 12.7% to $2.4 during Friday's after-market session. The company's market cap stands at $12.8 million.
    • Better Therapeutics (NASDAQ:BTTX) shares declined by 7.4% to $0.04. The company's market cap stands at $2.2 million.
    • PaxMedica (NASDAQ:PXMD) stock fell 6.28% to $0.7. The market value of their outstanding shares is at $5.1 million.
    • Aligos Therapeutics (NASDAQ:ALGS) shares declined by 5.26% to $0.9. The market value of their outstanding shares is at $68.1 million. As per the news, the Q4 earnings report came out 3 days ago.
    • Autolus Therapeutics (NASDAQ:AUTL) shares fell 4.99% to $5.53. The market value of their outstanding shares is at $1.2 billion. As per the press release, Q4 earnings came out yesterday.
    • Mersana Therapeutics (NASDAQ:MRSN) stock decreased by 4.97% to $4.79. The market value of their outstanding shares is at $581.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $ALGS
    $ATXI
    $AUTL

    CompanyDatePrice TargetRatingAnalyst
    Aligos Therapeutics Inc.
    $ALGS
    3/19/2026$48.00Buy
    Jefferies
    Autolus Therapeutics plc
    $AUTL
    2/17/2026$9.00Buy
    H.C. Wainwright
    Aligos Therapeutics Inc.
    $ALGS
    8/18/2025$50.00Buy
    H.C. Wainwright
    OptiNose Inc.
    $OPTN
    3/20/2025Buy → Hold
    Lake Street
    Mersana Therapeutics Inc.
    $MRSN
    2/6/2025Outperform
    William Blair
    OptiNose Inc.
    $OPTN
    1/3/2025$5.00 → $18.00Buy
    H.C. Wainwright
    Autolus Therapeutics plc
    $AUTL
    11/18/2024$7.00 → $7.60Neutral → Buy
    Goldman
    Mersana Therapeutics Inc.
    $MRSN
    11/15/2024$5.00Buy
    Citigroup
    More analyst ratings

    $ACON
    $ALGS
    $ATXI
    $AUTL
    SEC Filings

    View All

    Aclarion Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - Aclarion, Inc. (0001635077) (Filer)

    3/19/26 4:15:14 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form 8-A12B filed by Aclarion Inc.

    8-A12B - Aclarion, Inc. (0001635077) (Filer)

    3/19/26 4:05:11 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Aclarion Inc.

    10-K - Aclarion, Inc. (0001635077) (Filer)

    3/18/26 4:57:42 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    $ALGS
    $ATXI
    $AUTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Piccina Cintia

    3 - Autolus Therapeutics plc (0001730463) (Issuer)

    3/18/26 8:40:01 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Butitta Cynthia M

    3 - Autolus Therapeutics plc (0001730463) (Issuer)

    3/18/26 8:01:43 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Leiderman Elisabeth

    3 - Autolus Therapeutics plc (0001730463) (Issuer)

    3/18/26 8:00:44 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $ALGS
    $ATXI
    $AUTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

    BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (NASDAQ:ACON, ACONW)) ("Aclarion" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan is effective immediately and expires in one year. The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to

    3/19/26 9:25:40 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

    Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong Balance Sheet with Cash Runway into 2028 BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company's

    3/19/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet

    BROOMFIELD, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it will participate in the 38th Annual ROTH Conference, March 22-24, 2026, in Dana Point, CA. During the conference, CEO Brent Ness will engage in one-on-one meetings with institutional investors and analysts to discuss the company's progress advancing Nociscan, the company's proprietary MR spectroscopy platform designed to help physicians identify p

    3/17/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    $ALGS
    $ATXI
    $AUTL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ACON
    $ALGS
    $ATXI
    $AUTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Aligos Therapeutics with a new price target

    Jefferies resumed coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $48.00

    3/19/26 8:25:43 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Autolus Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $9.00

    2/17/26 8:13:55 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Aligos Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $50.00

    8/18/25 8:55:27 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $ALGS
    $ATXI
    $AUTL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    Large owner Giustra Frank bought $734,725 worth of shares (178,205 units at $4.12) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    9/15/25 8:19:20 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Kranzler Jay D bought $1,250 worth of shares (500 units at $2.50), increasing direct ownership by 417% to 620 units (SEC Form 4)

    4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

    10/1/24 4:15:13 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ALGS
    $ATXI
    $AUTL
    Leadership Updates

    Live Leadership Updates

    View All

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (("Aligos", NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective immediately. Mr. Hassard will lead and build the Company's global commercial capabilities and serve as a member of Aligos' Senior Leadership Team. Mr. Hassard is a seasoned executive with extensive experience building commercial organizations across multiple therapeutic areas. "As we continue to progress the Phase 2 B-

    1/13/26 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

    Marks Aclarion's first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgeryExperiencing strong commercial traction in UK as first market worldwide with private insurers covering NociscanNociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives BROOMFIELD, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announc

    11/5/25 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    $ALGS
    $ATXI
    $AUTL
    Financials

    Live finance-specific insights

    View All

    Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

    BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (NASDAQ:ACON, ACONW)) ("Aclarion" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan is effective immediately and expires in one year. The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to

    3/19/26 9:25:40 AM ET
    $ACON
    Medical Specialities
    Health Care

    Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

    LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results and operational highlights before open of U.S. markets on Friday, March 27, 2026. Management will host a conference call and webcast at 8:30am EDT / 12:30pm GMT to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN,

    3/16/26 4:10:00 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results

    Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc.Agreement provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 millionClosing is expected to occur by the end of January 2026 CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter e

    11/14/25 7:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ALGS
    $ATXI
    $AUTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by OptiNose Inc.

    SC 13G - OptiNose, Inc. (0001494650) (Subject)

    11/20/24 5:21:26 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care